Characteristics of patients with laBCC enrolled in Study 16201

Chart, study 1620 patient characteristics: laBCC (N=84)

Reason for HHI discontinuation*

All patients were previously treated with HHIs (n=84)1

75%

Disease progression/
lack of response2

25%

Intolerance to
HHI therapy2

  • *Investigators were allowed to select more than one reason for discontinuation of prior HHI therapy for an individual patient.2
  • BCC=basal cell carcinoma; ECOG=Eastern Cooperative Oncology Group; HHI=hedgehog inhibitor; PD-L1=programmed death ligand 1; TMB=tumor mutational burden.
No PD-L1 or TMB testing is required before starting LIBTAYO in locally advanced BCC.1,2

References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.